Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
8214- LCA,    Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade
- vitro+vivo, AML, U937
TumCP↓, Ferroptosis↑, IGF2BP3/IMP3/KOC↓, MDM2↓,
8215- LCA,    Determination of licochalcone A in rat plasma by UPLC–MS/MS and its pharmacokinetics
- in-vivo, Nor, NA
*BioAv↓,
8216- LCA,    Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A
- in-vivo, Nor, NA
*Dose↝, *CYP3A4↓, *P-gp/ABCB1↓,
8217- LCA,    Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice
- Study, Nor, NA
*CYP1A1↓, *CYP2C19↓, *CYP2C8↓, *CYP2C9↓, *CYP3A4↓, *CYP2E1↓, *CYP2D6↓, *BioEnh↑, eff↑,
8218- LCA,    Advances in Pharmacological Activities and Drug Delivery Systems of Licochalcone A
- Review, Nor, NA
*Inflam↓, *antiOx↑, *AntiTum↑, *hepatoP↑, *Bacteria↓, AntiCan↑, BioAv↓, BioAv↑,
8219- LCA,    Licochalcone A Ameliorates Cognitive Dysfunction in an Alzheimer's Disease Model by Inhibiting Endoplasmic Reticulum Stress-Mediated Apoptosis
- in-vivo, AD, NA
*Dose↝, *cognitive↑, *Aβ↓, *ER Stress↓, *BioAv↑, *toxicity↓, *PERK↓, *eIF2α↓, *ATF4↓, *CHOP/DDIT3↓, *NRF2↑,
8220- LCA,    Licochalcone a enhances cognitive resilience in APP/PS1 Mice by modulating glucose metabolism, Aβ burden, and neuroinflammation
- in-vivo, AD, NA
*Dose↝, *memory↑, *PSD95↑, *Ki-67↑, *GLUT1↑, *Aβ↓, *Aβ42↓, *Inflam↓, *TREM2↓, *cognitive↑,
8221- LCA,    Anti-inflammatory efficacy of Licochalcone A: correlation of clinical potency and in vitro effects
- in-vitro, Nor, NA
*Inflam↓, *AntiBio↑, *PGE2↓, *IL6↓, *TNF-α↓,
8222- LCA,    Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways
- in-vitro, CCA, KKU-100 - in-vitro, CCA, KKU-213 - in-vitro, CCA, KKU-214 - in-vitro, CCA, KKU-156 - in-vitro, 0-Reserved, KKU-452
TumCP?, TumCD?, ROS↑, NRF2↓, BAX↑, Cyt‑c↑, TumCMig↓, TumCCA↑, NF-kB↓, STAT3↓, cycD1/CCND1↓, VEGF↓, ICAM-1↓,
8223- LCA,    Lico A Enhances Nrf2-Mediated Defense Mechanisms against t-BHP-Induced Oxidative Stress and Cell Death via Akt and ERK Activation in RAW 264.7 Cells
- in-vitro, Nor, RAW264.7
*Apoptosis↓, *ROS↓, *GSH↑, *GCLM↑, *GCLC↑, *HO-1↑, *NRF2↑, *Keap1↓, *ARE↑, *Akt↑, *ERK↑, *PI3K↑,
8224- LCA,    3,3',4,4'-Tetrahydroxy-2-methoxychalcone from Glycyrrhiza uralensis roots inhibits HIF-1α and Nrf2, suppressing hypoxia-induced angiogenesis
- in-vitro, CRC, HCT116
Hif1a↓, NRF2↓, VEGF↓, HO-1↓, ROS↓,
8225- LCA,  Cisplatin,    Licochalcone A protects against cisplatin-induced acute kidney injury via the modulation of Nrf2/Keap1-mediated ferroptosis and apoptosis
- in-vivo, Nor, NA
*RenoP↑, *Urea↓, *BUN↓, *creat↓, *Apoptosis↓, *Ferroptosis↓, *Iron↓, *ROS↓, *lipid-P↓, *mtDam↓, *NRF2↑,
8226- LCA,    Licochalcone A as a Potential Anti- Toxoplasma Agent: A Target Identification and Pharmacokinetic Study
- Study, Nor, NA
*BBB↑,
8227- LCA,    Licochalcone A as Novel Multitarget Inhibitors via AChE, BuChE, and Synapsin III for Therapeutic Intervention Against Alzheimer’s Disease: Computer-Aided Drug Design
- Study, AD, NA
*AChE↓, *BChE↓, *SYN3↓,
8228- LCA,    Detection and pharmacokinetics of licochalcone A in brains of neuroinflammatory mouse model
- in-vivo, AD, NA
*Inflam↓, *neuroP?, *BBB↑, *memory↑, *cognitive↑,
8264- LE,  ISL,    Glycyrrhiza glabra L. Extracts with Potential Antiproliferative and Anti-Migration Activities Against Breast and Gynecological Cancer Cell Lines
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, Melanoma, A2780S - in-vitro, Cerv, HeLa
eff↑, Dose↝, Dose↑,
8265- LE,    Glycyrrhizin ameliorates colorectal cancer progression by regulating NHEJ pathway through inhibiting HMGB1-induced DNA damage response
- vitro+vivo, CRC, NA
TumCG↓, Inflam↓, tumCV↓, DNAdam↑, Apoptosis↑, Casp3↑, TumCCA↑, cycD1/CCND1↓, HMGB1↓, NHEJ↓, TumCP↓,
8271- LE,    Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method
- Human, Nor, NA
*Dose?, *BioAv?,
8266- LE,    Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities
- Study, Nor, NA
*Inflam↓, *AntiViral↑, *HMGB1↓,
8267- LE,    Glycyrrhizin Attenuates the Process of Epithelial-to-Mesenchymal Transition by Modulating HMGB1 Initiated Novel Signaling Pathway in Prostate Cancer Cells
- in-vitro, Pca, DU145
HMGB1↓, TumMeta↓, EMT↓,
8268- LE,    Glycyrrhizin Attenuates Carcinogenesis by Inhibiting the Inflammatory Response in a Murine Model of Colorectal Cancer
- vitro+vivo, CRC, NA
AntiTum↑, IL6↓, CCN2/CTGF↓, Inflam↓, HMGB1↓, DNAdam↓, CSCs↓, TLR4↓, NF-kB↓,
8269- LE,    Glycyrrhiza glabra-Enhanced Extract and Adriamycin Antiproliferative Effect on PC-3 Prostate Cancer Cells
- in-vitro, Pca, PC3
TumCP↓, TumAuto↑, Apoptosis↑,
8270- LE,  Rad,    Comparative Study of the Effect of Licorice Muco-adhesive Film on Radiotherapy Induced Oral Mucositis, A Randomized Controlled Clinical Trial
- Trial, HNSCC, NA
Dose?, Pain↓, Mucositis↓,
8263- LE,    Glycyrrhiza glabra L. suppress the proliferation of non-small cell lung cancer by inducing necrosis rather than apoptosis despite increasing bax level
- in-vitro, Lung, A549
BAX↑, necrosis↑, Dose↝,
8262- LE,    Phytochemical profiling, antimicrobial, cytotoxic and apoptotic effects of Glycyrrhiza glabra ethanolic extract
- in-vitro, Liver, HepG2
*Dose↝, *AntiBio↑, Dose↝, P53↑, BAX↑, Bcl-2↓, Apoptosis↑,
8240- LE,    Licorice flavonoids nanoparticles prepared by liquid antisolvent re-crystallization exhibit higher oral bioavailability and antioxidant activity in rat
- in-vivo, Nor, NA
*BioAv↑,
8236- LE,    Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects
- Review, Var, NA
Bcl-2↓, CDK2↓, PI3K↓, cJun↓, mTOR↓, NF-kB↓, VEGF↓, MMP3↓, toxicity↓, Dose↑, chemoP↑, *antiOx↑, *Inflam↓, Dose↝, *COX2/PTGS2↓, *iNOS↓, *IL6↓, *IL10↓, *PGE2↓, *IκB?, *NRF2↑, *HO-1↑, *lipid-P↓, *ROS↓, *Catalase↑, *GPx↑, *SOD↑, Apoptosis↑, ROS↑, TumCP↓, TumCCA↑, cycE/CCNE↓, cycD1/CCND1↓, p‑GSK‐3β↓, PI3K↓, MKK4↓, MKK7↓, HSP90↓, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1/ATG6↑, p62↓, p‑Akt↓, cl‑Casp9↑, cl‑Casp7↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Cyt‑c↑, P53↑, STAT3↓, E-cadherin↑, Vim↓, N-cadherin↓, CD31/PECAM-1↓, Hif1a↓, iNOS↓, DNAdam↑, MMP↓, BIM↑, APAF1↑, PCNA↓, toxicity↝, eff↑,
1040- LE,    Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration
- in-vivo, Lung, H1975
TumCCA↑, CDK4↓, cycD1/CCND1↓, PD-L1↑, TumVol↓,
1266- LE,    Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
HMGB1↓, EMT↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓,
1306- LE,    Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell
- in-vitro, BC, MCF7
Bcl-2↓, BAX↑, Apoptosis↑, TumCCA↑,
1788- LE,    Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of Glycyrrhiza glabra root
- in-vitro, BC, MCF7
TumCG↑,
1787- LE,    Licorice and cancer
- Review, Var, NA
Inflam↓, AntiCan↓, DNAdam↓, LOX1↓, COX2/PTGS2↓, PKCδ↓, EGFR↓,
2453- LE,    The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors
- Review, Var, NA
HK2↓, PI3K↓, Akt↓, TumCP↓, Glycolysis↓,
8181- LEC,  CUR,    Soybean lecithin-stabilized oil-in-water (O/W) emulsions increase the stability and in vitro bioaccessibility of bioactive nutrients
- in-vitro, Nor, NA
*BioEnh↑, *Dose↝,
3706- LEC,    Lecithin for dementia and cognitive impairment
- Review, AD, NA
*cognitive∅,
1789- LEC,    Lecithin Supplements and Breast Cancer Risk
- Analysis, NA, NA
AntiCan↑, Risk↓,
1790- LEC,  DHA,    Dietary Crude Lecithin Increases Systemic Availability of Dietary Docosahexaenoic Acid with Combined Intake in Rats
- in-vivo, Nor, NA
*eff↑, other↑,
1791- LEC,    Vegetable lecithins: A review of their compositional diversity, impact on lipid metabolism and potential in cardiometabolic disease prevention
- Review, Nor, NA
*BioEnh↑, *antiOx↑, *BioEnh↑, *LDL↓, *HDL∅, *Obesity↓, eff↑, GutMicro↝,
1793- LEC,    Unmasking Sunflower Lecithin: Does Science Support the Claims?
- Review, NA, NA
BioEnh↑, memory↑, Inflam↓, GutMicro↑, antiOx↑,
1794- LEC,    Effects of abomasal infusion of soybean or sunflower lecithin on nutrient digestibility and milk production in lactating dairy cows
- in-vivo, NA, NA
BioAv↑, other↑,
1795- LEC,  Chit,    Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene
- in-vivo, Nor, NA
eff↑, BioAv↑,
1796- LEC,    A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin
- Review, NA, NA
BioAv↑, antiOx↑, LDL↓, memory↑,
4233- LEC,    Lecithinized brain-derived neurotrophic factor promotes the differentiation of embryonic stem cells in vitro and in vivo
- in-vitro, Nor, NA
*BDNF↑, *motorD↑, *Diff↑,
8130- LF,    Lactoferrin targeting INTL1 receptor inhibits hepatocellular carcinoma progression via apoptosis and cell cycle signaling pathways
- in-vitro, HCC, HepG2 - in-vitro, HCC, HepG3 - in-vitro, HCC, SK-HEP-1
Iron↓, TumCP↓, selectivity↑, TumCCA↑, p‑MAPK↑, JNK↑, Apoptosis↑,
8145- LF,    Neuroprotective Effects of Lactoferrin in Alzheimer's and Parkinson's Diseases: A Narrative Review
- Review, AD, NA - Review, Park, NA
*AntiBio↑, *Imm↑, *AntiCan↑, *neuroP↑, *BBB↑, *APOE4↓, *ROS↓, *Inflam↓, *Apoptosis↓, *Learn↑, *memory↑, *ADAM10↑, *PSEN1/PS1↑, *cl‑APP↑, *BACE/β-secretase↓, *cognitive↑, *MDA↓, *IL6↓, *TNF-α↓, *neuroP↑, *Dose↝, *IronCh↑, *SOD↑, *BioAv↝,
8123- LF,    Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial
- Trial, CRC, NA
AntiCan↑, Dose↝, APG↓,
8124- LF,    Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine
- Trial, CRC, NA
Risk↓, Dose↝, NK cell↑, Neut↑, CD4+↑, Imm↑, APG↓,
8125- LF,    Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
- Trial, NSCLC, NA
Dose?, eff∅,
8126- LF,    Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy
- NA, NSCLC, NA
Dose↝, OS↑, PFS↑, DCR↑, other↝,
8127- LF,    Phase I trial of oral talactoferrin alfa in refractory solid tumors
- Trial, Var, NA
Imm↑, NK cell↑, Dose↝, toxicity↓, IL18↑, SD↑, TumCG↓, OS↑,

Showing Research Papers: 5401 to 5450 of 8269
Prev Page 109 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

APG↓, 2,   DCR↑, 1,   IGF2BP3/IMP3/KOC↓, 1,   Mucositis↓, 1,   NHEJ↓, 1,   PFS↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Ferroptosis↑, 1,   HO-1↓, 1,   Iron↓, 1,   NRF2↓, 2,   ROS↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MKK4↓, 1,   MKK7↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Glycolysis↓, 1,   HK2↓, 1,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↑, 6,   BAX↑, 5,   Bcl-2↓, 3,   BIM↑, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   cl‑Casp7↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 2,   Ferroptosis↑, 1,   iNOS↓, 1,   JNK↑, 1,   p‑MAPK↑, 1,   MDM2↓, 1,   necrosis↑, 1,   TumCD?, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   other↑, 2,   other↝, 1,   SD↑, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP90↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 2,   DNAdam↑, 2,   P53↑, 2,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   EMT↓, 2,   p‑GSK‐3β↓, 1,   mTOR↓, 1,   PI3K↓, 3,   STAT3↓, 2,   TumCG↓, 2,   TumCG↑, 1,  

Migration(tgid=13) ⓘ

CCN2/CTGF↓, 1,   CD31/PECAM-1↓, 1,   E-cadherin↑, 1,   MMP3↓, 1,   N-cadherin↓, 1,   PKCδ↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   TumCMig↓, 2,   TumCP?, 1,   TumCP↓, 6,   TumMeta↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   Hif1a↓, 2,   LOX1↓, 1,   VEGF↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   COX2/PTGS2↓, 1,   HMGB1↓, 4,   ICAM-1↓, 1,   IL18↑, 1,   IL6↓, 1,   Imm↑, 2,   Inflam↓, 4,   Neut↑, 1,   NF-kB↓, 3,   NK cell↑, 2,   PD-L1↑, 1,   TLR4↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 4,   BioEnh↑, 1,   Dose?, 2,   Dose↑, 2,   Dose↝, 8,   eff↑, 5,   eff∅, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   GutMicro↑, 1,   GutMicro↝, 1,   IL6↓, 1,   PD-L1↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 3,   AntiTum↑, 1,   chemoP↑, 1,   memory↑, 2,   OS↑, 2,   Pain↓, 1,   Risk↓, 2,   toxicity↓, 2,   toxicity↝, 1,   TumVol↓, 1,  
Total Targets: 121

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 3,   APOE4↓, 1,   Aβ42↓, 1,   CYP2C19↓, 1,   CYP2C8↓, 1,   CYP2D6↓, 1,   Learn↑, 1,   PSEN1/PS1↑, 1,   SYN3↓, 1,   TREM2↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   ARE↑, 1,   Catalase↑, 1,   CYP1A1↓, 1,   CYP2E1↓, 1,   Ferroptosis↓, 1,   GCLC↑, 1,   GCLM↑, 1,   GPx↑, 1,   GSH↑, 1,   HDL∅, 1,   HO-1↑, 2,   Iron↓, 1,   Keap1↓, 1,   lipid-P↓, 2,   MDA↓, 1,   NRF2↑, 4,   ROS↓, 4,   SOD↑, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

BUN↓, 1,   CYP3A4↓, 2,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Apoptosis↓, 3,   Ferroptosis↓, 1,   iNOS↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   eIF2α↓, 1,   ER Stress↓, 1,   PERK↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 1,   ERK↑, 1,   PI3K↑, 1,  

Migration(tgid=13) ⓘ

cl‑APP↑, 1,   Ki-67↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

ATF4↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 3,   GLUT1↑, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   HMGB1↓, 1,   IL10↓, 1,   IL6↓, 3,   Imm↑, 1,   Inflam↓, 7,   IκB?, 1,   PGE2↓, 2,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   ADAM10↑, 1,   BChE↓, 1,   BDNF↑, 1,   PSD95↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,   BACE/β-secretase↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv?, 1,   BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 1,   BioEnh↑, 4,   CYP2C9↓, 1,   Dose?, 1,   Dose↝, 6,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

creat↓, 1,   IL6↓, 3,   Ki-67↑, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cognitive↑, 4,   cognitive∅, 1,   hepatoP↑, 1,   memory↑, 3,   motorD↑, 1,   neuroP?, 1,   neuroP↑, 2,   Obesity↓, 1,   RenoP↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 94

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page